Goldshield Group Plc is a marketing-led, British pharmaceutical and healthcare company. Growth has been rapid and achieved both organically and through astute product acquisition.

Goldshield Critical Care Europe - a division of Goldshield Pharmaceuticals - is one of the largest suppliers of small volume parenteral products to UK National Health Service and health sectors within the U.K., Republic of Ireland and other European markets.

Goldshield Critical Care Europe has earned a reputation of modifying established products to ensure safer administration and more appropriate presentations. This has included initiatives from safer labelling and packaging formats to innovative new presentations of products, such as our Bupivacaine infusion solution, which was the first product licensed to cater for the trend towards continuous postoperative epidural infusions and mobile epidurals during labour, utilising lower concentrations of the drug.  The company also promotes several specialised branded pharmaceutical products to the hospital sector such as Robinul (glycopyrrolate) a preoperative antimuscarinic drug to reduce secretions, Dopram (Doxapram) a peripheral respiratory stimulant, Pitressin 20IU argipressin presentation, AutoDetect a spring loaded loss of resistance syringe for epidural and laparoscopic procedure, Noseeze a natural product for management of dryness and crusting of epithelium caused by oxygen therapy, low humidity, air conditioned environments and as a side effect of radiation therapy. Goldshield Critical Care Europe are the exclusive distributor for United Therapeutics Inc. in UK and Republic of Ireland for a new chemical entity for the management of pulmonary arterial hypertension.